GB2563531B - Heterodimers and purification thereof - Google Patents

Heterodimers and purification thereof Download PDF

Info

Publication number
GB2563531B
GB2563531B GB1814284.4A GB201814284A GB2563531B GB 2563531 B GB2563531 B GB 2563531B GB 201814284 A GB201814284 A GB 201814284A GB 2563531 B GB2563531 B GB 2563531B
Authority
GB
United Kingdom
Prior art keywords
heterodimers
purification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1814284.4A
Other versions
GB201814284D0 (en
GB2563531A (en
Inventor
C Jones Philip
Stadlmayr Gerhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agga Ltd
Original Assignee
Agga Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agga Ltd filed Critical Agga Ltd
Publication of GB201814284D0 publication Critical patent/GB201814284D0/en
Publication of GB2563531A publication Critical patent/GB2563531A/en
Application granted granted Critical
Publication of GB2563531B publication Critical patent/GB2563531B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GB1814284.4A 2016-02-05 2017-02-02 Heterodimers and purification thereof Active GB2563531B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1602156.0A GB201602156D0 (en) 2016-02-05 2016-02-05 Heterodimers and purification thereof
PCT/GB2017/050257 WO2017134440A2 (en) 2016-02-05 2017-02-02 Heterodimers and purification thereof

Publications (3)

Publication Number Publication Date
GB201814284D0 GB201814284D0 (en) 2018-10-17
GB2563531A GB2563531A (en) 2018-12-19
GB2563531B true GB2563531B (en) 2020-05-13

Family

ID=55641913

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1602156.0A Ceased GB201602156D0 (en) 2016-02-05 2016-02-05 Heterodimers and purification thereof
GB1814284.4A Active GB2563531B (en) 2016-02-05 2017-02-02 Heterodimers and purification thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB1602156.0A Ceased GB201602156D0 (en) 2016-02-05 2016-02-05 Heterodimers and purification thereof

Country Status (2)

Country Link
GB (2) GB201602156D0 (en)
WO (1) WO2017134440A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191438A1 (en) 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20210006913A (en) 2018-04-11 2021-01-19 인히브릭스, 인크. Multispecific polypeptide constructs with limited CD3 binding and related methods and uses
CN112789294A (en) 2018-07-24 2021-05-11 印希比股份有限公司 Multispecific polypeptide constructs containing constrained CD3 binding domains and receptor binding regions and methods of use thereof
SG11202101369XA (en) * 2018-08-17 2021-03-30 Regeneron Pharma Method and chromatography system for determining amount and purity of a multimeric protein
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CN113166261A (en) 2018-10-11 2021-07-23 印希比股份有限公司 B7H3 single domain antibodies and therapeutic compositions thereof
US20210340273A1 (en) 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
AU2019384790A1 (en) 2018-11-21 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-staphylococcus antibodies and uses thereof
MA56205A (en) 2019-06-11 2022-04-20 Regeneron Pharma ANTI-PCRV ANTIBODIES WHICH BIND TO PCRV, COMPOSITIONS COMPRISING ANTI-PCRV ANTIBODIES, AND METHODS OF USE THEREOF
WO2020252260A1 (en) * 2019-06-13 2020-12-17 Regeneron Pharmaceuticals, Inc. Methods for removing undesired components during multistage chromatographic processes
BR112022014667A2 (en) 2020-01-29 2022-09-20 Inhibrx Inc CD28 SINGLE DOMAIN ANTIBODIES AND MULTIVALENT AND MULTISPECIFIC CONSTRUCTS THEREOF
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011078332A1 (en) * 2009-12-25 2011-06-30 中外製薬株式会社 Polypeptide modification method for purifying polypeptide multimers
WO2014049003A1 (en) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011078332A1 (en) * 2009-12-25 2011-06-30 中外製薬株式会社 Polypeptide modification method for purifying polypeptide multimers
WO2014049003A1 (en) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IRINA S. MOREIRA ET AL: 'Unraveling the Importance of Protein-Protein Interaction: Application of a Computational Alanine-Scanning Mutagenesis to the Study of the IgGl Streptococcal Protein G (C2 Fragment) Complex',THE JOURNAL OF PHYSICAL CHEMISTRY B, vol. 110, no. 22, 1 June 2006 *
JENDEBERG L ET AL: "Engineering of Fcl and Fc3 from human immunoglobulin G toanalyse subclass specificity for staphylococcal protein A", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL,vol. 201, no. l,14 February 1997 (1997-02-14), pages25-34, XP *
K N POTTER, YUCHENG LI, J DONALD CAPRA2F3, E, C DOMAINS, E: "Staphylococcal protein A simultaneously interacts with framework region 1, complementarity-determining region 2, and framework region 3 on human VH3-encoded Igs", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950), AM ASSOC IMMNOL, UNITED STATES, 1 October 1996 (1996-10-01), UNITED STATES, pages 2982, XP055098543, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/8816406> *
SAUER-ERIKSSON, A.E. KLEYWEGT, G.J. UHLEN, M. JONES, T.A.: "Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG", STRUCTURE, ELSEVIER, AMSTERDAM, NL, vol. 3, no. 3, 1 March 1995 (1995-03-01), AMSTERDAM, NL, pages 265 - 278, XP004587842, ISSN: 0969-2126, DOI: 10.1016/S0969-2126(01)00157-5 *

Also Published As

Publication number Publication date
WO2017134440A2 (en) 2017-08-10
WO2017134440A3 (en) 2017-10-19
GB201602156D0 (en) 2016-03-23
GB201814284D0 (en) 2018-10-17
GB2563531A (en) 2018-12-19

Similar Documents

Publication Publication Date Title
GB2563531B (en) Heterodimers and purification thereof
IL261442A (en) Tgfb1-binding immunoglobulins and use thereof
HK1243741A1 (en) Tnfrsf-binding agents and uses thereof
IL255577B (en) Tigit-binding agents and uses thereof
HK1256419A1 (en) Acetamide thienotriazolodiazepines and uses thereof
IL262926A (en) Mic-1 compounds and use thereof
HK1252227A1 (en) Fastening system and use thereof
SG11201706029VA (en) Anti-senescence compounds and uses thereof
HK1246780A1 (en) Aza-pyridone compounds and uses thereof
ZA201705456B (en) Benzoxaborole compounds and uses thereof
IL254241A0 (en) Etv2 and uses thereof
IL264473A (en) Gpr156 variants and uses thereof
IL253800B (en) Trans-2-octenal ans use thereof
IL253459A0 (en) Isoergoline compounds and uses thereof
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
IL264751A (en) Purification systems and methods
GB201614224D0 (en) Compounds and uses thereof
IL265617B (en) 1-phenylpropanone compounds and use thereof
GB2545167B (en) Cloches and use thereof
GB201613134D0 (en) Novel compounds and their use
GB201514770D0 (en) Compounds and their use
GB201513318D0 (en) Novel compounds and their use
GB201500278D0 (en) Novel combination and use
GB201503258D0 (en) Rehydration and purification device

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20190103 AND 20190109